| Phase 3 |
| NCT05613023 |
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT |
Prostate Cancer |
Recruiting |
2024-09-19 |
| NCT02305654 |
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) |
Squamous Cell Carcinoma of the Penis, Usual Type |
Active, Not Recruiting |
2026-08-31 |
| NCT04584853 |
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib |
Breast Cancer Female |
Active, Not Recruiting |
2026-01-14 |
| NCT02338310 |
Trial of Perioperative Endocrine Therapy - Individualising Care |
Breast Cancer |
Active, Not Recruiting |
2020-02-17 |
| Phase 2 |
| NCT05990192 |
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian… |
Ovarian Cancer Recurrent |
Recruiting |
2026-07-13 |
| NCT03740893 |
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical… |
Breast Neoplasm |
Recruiting |
2025-08-11 |
| NCT03946202 |
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally… |
Breast Cancer |
Active, Not Recruiting |
2026-09-02 |
| NCT04065269 |
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological… |
Gynaecological Cancers |
Active, Not Recruiting |
2026-02-20 |
| NCT02955082 |
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment |
Hormone Refractory Prostate Cancer |
Active, Not Recruiting |
2026-02-04 |
| NCT02447549 |
Study of Tumour Focused Radiotherapy for Bladder Cancer |
Bladder Cancer |
Active, Not Recruiting |
2020-06-09 |
| Phase 1/2 |
| NCT07002320 |
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant… |
Metastatic Castrate-Resistant Prostate Cancer (mCRPC) |
Recruiting |
2026-09-08 |
| NCT07718243 |
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma… |
Melanoma (Skin Cancer) |
Recruiting |
2026-09-08 |
| NCT07391215 |
5G-PEARL: Paxalisib in Malignant Brain Tumours |
Malignant Primary Gliomas |
Recruiting |
2026-02-05 |
| NCT06630260 |
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours |
Glioblastoma Multiforme (GBM) |
Recruiting |
2026-01-21 |
| NCT06126731 |
Combination Study of Antibiotics With Enzalutamide (PROMIZE) |
Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Recruiting |
2025-11-24 |
| NCT03673787 |
A Trial of Ipatasertib in Combination With Atezolizumab |
Solid Tumor |
Active, Not Recruiting |
2025-05-14 |
| Phase 1 |
| NCT06976892 |
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer |
High Grade Serous Ovarian Cancer |
Recruiting |
2025-08-13 |
| NCT06632236 |
5G-EMERALD: Amivantamab in Malignant Brain Tumours |
Malignant Primary Gliomas |
Active, Not Recruiting |
2026-08-17 |
| NCT05082259 |
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab |
Advanced Cancer |
Active, Not Recruiting |
2026-06-25 |
| NCT05782361 |
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC |
Advanced Cancer |
Active, Not Recruiting |
2026-04-24 |
| NCT03875820 |
Phase I Trial of Defactinib and VS-6766. |
NSCLC |
Active, Not Recruiting |
2026-03-10 |
| Not applicable |
| NCT04595019 |
Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer |
Prostate Cancer |
Recruiting |
2022-06-13 |
| Not specified |
| NCT07737509 |
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response… |
Advanced Solid Tumours |
Recruiting |
2026-07-31 |
| NCT05810467 |
The Active Surveillance Study |
Prostate Cancer |
Recruiting |
2026-02-04 |
| NCT06636526 |
The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups… |
Prostate Cancer |
Recruiting |
2026-02-04 |